Easywell Biomedicals (1799) reported revenue of NT$67.7 million for Oct 2026, +128.2% year on year and -51.1% from the previous month. Revenue for Jan–Oct 2026 was NT$845 million (+81.8% year on year).
Year-on-year revenue growth: 10 months in a row. →
In Oct 2026, it ranked No. 91 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$67.7 million | +128.2% | -51.1% |
| Sep 2026 | NT$138.5 million | +80.6% | +28.5% |
| Aug 2026 | NT$107.8 million | +82.4% | +59.2% |
| Jul 2026 | NT$67.7 million | +74.9% | -16.7% |
| Jun 2026 | NT$81.3 million | +67.0% | +42.9% |
| May 2026 | NT$56.8 million | +64.3% | -35.8% |
| Apr 2026 | NT$88.5 million | +240.4% | -11.6% |
| Mar 2026 | NT$100.1 million | +30.6% | +69.3% |
| Feb 2026 | NT$59.1 million | +38.6% | -23.7% |
| Jan 2026 | NT$77.4 million | +140.2% | +14.7% |
| Dec 2025 | NT$67.5 million | -1.3% | +3.8% |
| Nov 2025 | NT$65 million | +72.9% | +119.0% |
| Oct 2025 | NT$29.7 million | -37.7% | -61.3% |
| Sep 2025 | NT$76.6 million | +14.3% | +29.7% |
| Aug 2025 | NT$59.1 million | +13.5% | +52.6% |
| Jul 2025 | NT$38.7 million | -45.8% | -20.5% |
| Jun 2025 | NT$48.7 million | -20.7% | +40.6% |
| May 2025 | NT$34.6 million | -6.2% | +33.0% |
| Apr 2025 | NT$26 million | +5.6% | -66.1% |
| Mar 2025 | NT$76.6 million | +57.7% | +79.6% |
| Feb 2025 | NT$42.7 million | +199.0% | +32.4% |
| Jan 2025 | NT$32.2 million | +205.2% | -52.9% |
| Dec 2024 | NT$68.4 million | +1.1% | +81.9% |
| Nov 2024 | NT$37.6 million | +451.9% | -21.1% |
| Oct 2024 | NT$47.6 million | +111.1% | -28.9% |
Jan–Oct 2026 cumulative: NT$845 million (+81.8% YoY)
Other Biotech & Medical companies
Compare with peers: Easywell Biomedicals vs PEC / Easywell Biomedicals vs Lotus Pharm / Easywell Biomedicals vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
因新藥/學名藥產品出貨較去年同期多,故營收成長。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16